- Home
- ADXN vs GOVX Comparison
ADXN vs GOVX Comparison
Compare ADXN & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADXN
- GOVX
- Stock Information
- Founded
- ADXN 2002
- GOVX 2001
- Country
- ADXN Switzerland
- GOVX United States
- Employees
- ADXN N/A
- GOVX N/A
- Industry
- ADXN Biotechnology: Pharmaceutical Preparations
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- ADXN Health Care
- GOVX Health Care
- Exchange
- ADXN Nasdaq
- GOVX Nasdaq
- Market Cap
- ADXN 8.0M
- GOVX 7.6M
- IPO Year
- ADXN N/A
- GOVX N/A
- Fundamental
- Price
- ADXN $10.70
- GOVX $0.70
- Analyst Decision
- ADXN Strong Buy
- GOVX Strong Buy
- Analyst Count
- ADXN 1
- GOVX 3
- Target Price
- ADXN $30.00
- GOVX $10.67
- AVG Volume (30 Days)
- ADXN 58.4K
- GOVX 690.2K
- Earning Date
- ADXN 09-01-2025
- GOVX 11-11-2025
- Dividend Yield
- ADXN N/A
- GOVX N/A
- EPS Growth
- ADXN N/A
- GOVX N/A
- EPS
- ADXN 0.10
- GOVX N/A
- Revenue
- ADXN $278,508.00
- GOVX $6,143,044.00
- Revenue This Year
- ADXN $86.57
- GOVX N/A
- Revenue Next Year
- ADXN N/A
- GOVX N/A
- P/E Ratio
- ADXN $0.85
- GOVX N/A
- Revenue Growth
- ADXN N/A
- GOVX 1943.07
- 52 Week Low
- ADXN $6.51
- GOVX $0.43
- 52 Week High
- ADXN $12.05
- GOVX $3.88
- Technical
- Relative Strength Index (RSI)
- ADXN 78.58
- GOVX 44.16
- Support Level
- ADXN $7.70
- GOVX $0.65
- Resistance Level
- ADXN $8.21
- GOVX $0.73
- Average True Range (ATR)
- ADXN 0.22
- GOVX 0.04
- MACD
- ADXN 0.20
- GOVX -0.00
- Stochastic Oscillator
- ADXN 68.97
- GOVX 33.72
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.